Sartorius Stedim Biotech : No relief before Q3 – Q2 expected to remain weak
>Revisiting our model - Following recent results, the closing of the takeover of Polyplus and change in coverage, we revise our model. We continue to expect Sartorius Stedim to profit from high underlying demand for bioprocess solutions. However, the current destocking in the biopharma industry as well as the decline of Covid-related revenues have become a burden on the order book as well as on revenue development. On the back of the recent harsh guidance cut, we do n...Sartorius Stedim Biotech is a provider of equipment and services for the development, quality assurance and production processes of the biopharmaceutical industry. Co.'s solutions cover fermentation, filtration, purification, fluid management and lab technologies and membrane chromatography, including various conventional lab products to biopharmaceutical laboratories. Co.'s technologies, products and services are used to develop and manufacture medications and vaccines using biological methods. Co.'s products covers all upstream and downstream steps in the production of active pharmaceutical ingredients. It specializes in single-use products and offers technical consulting and services.
Oddo Securities provides securities brokerage and research services. The company offers equity, economic, and derivatives research and credit analysis services. It focuses on insurance, automotive, building materials, pharmaceuticals, telecommunications, information technology, and agri-food industries.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.